Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ichiro Maruko

Showing results (101-110 of 111) with videos related to

Pageof 12
Sort By:
Japanese Journal of Ophthalmology|July 6, 2018
Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathyMasashi Ogasawara, Hideki Koizumi, Akiko Yamamoto, et al.
Ophthalmology. Retina|May 18, 2020
Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration: A Prospective StudyIchiro Maruko, Masashi Ogasawara, Akiko Yamamoto, et al.
BMJ Open|April 21, 2026
Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trialMasahiro Miyake, Ayako Takahashi, Takayuki Baba, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|January 16, 2022
Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter studyTamaki Tamashiro, Koji Tanaka, Kanako Itagaki, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|October 13, 2025
Treatment outcomes of switching to aflibercept 8 mg in previously-treated neovascular age-related macular degenerationKeiko Kataoka, Koji Tanaka, Junichiro Honjyo, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|September 5, 2023
Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degenerationKeiko Kataoka, Kanako Itagaki, Nozumu Hashiya, et al.
Scientific Reports|May 22, 2024
One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in JapanRyo Mukai, Keiko Kataoka, Koji Tanaka, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|March 16, 2021
Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter studyIchiro Maruko, Annabelle A Okada, Tomohiro Iida, et al.
Scientific Reports|May 30, 2023
Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in JapanRyo Mukai, Keiko Kataoka, Koji Tanaka, et al.
Japanese Journal of Ophthalmology|May 20, 2022
Short-term results for brolucizumab in treatment-naïve neovascular age-related macular degeneration: a Japanese multicenter studyKoji Tanaka, Hideki Koizumi, Tamaki Tamashiro, et al.
Pageof 12

Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
Japanese Journal of Ophthalmology|July 6, 2018
Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathyMasashi Ogasawara, Hideki Koizumi, Akiko Yamamoto, et al.
Ophthalmology. Retina|May 18, 2020
Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration: A Prospective StudyIchiro Maruko, Masashi Ogasawara, Akiko Yamamoto, et al.
BMJ Open|April 21, 2026
Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trialMasahiro Miyake, Ayako Takahashi, Takayuki Baba, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|January 16, 2022
Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter studyTamaki Tamashiro, Koji Tanaka, Kanako Itagaki, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|October 13, 2025
Treatment outcomes of switching to aflibercept 8 mg in previously-treated neovascular age-related macular degenerationKeiko Kataoka, Koji Tanaka, Junichiro Honjyo, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|September 5, 2023
Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degenerationKeiko Kataoka, Kanako Itagaki, Nozumu Hashiya, et al.
Scientific Reports|May 22, 2024
One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in JapanRyo Mukai, Keiko Kataoka, Koji Tanaka, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|March 16, 2021
Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter studyIchiro Maruko, Annabelle A Okada, Tomohiro Iida, et al.
Scientific Reports|May 30, 2023
Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in JapanRyo Mukai, Keiko Kataoka, Koji Tanaka, et al.
Japanese Journal of Ophthalmology|May 20, 2022
Short-term results for brolucizumab in treatment-naïve neovascular age-related macular degeneration: a Japanese multicenter studyKoji Tanaka, Hideki Koizumi, Tamaki Tamashiro, et al.
Pageof 12